The glycosylation in SARS-CoV-2 and its receptor ACE2

Y Gong, S Qin, L Dai, Z Tian - Signal Transduction and Targeted …, 2021 - nature.com
Abstract Coronavirus disease 2019 (COVID-19), a highly infectious disease caused by
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has infected more than …

A state-of-the-art review on fucoidan as an antiviral agent to combat viral infections

B Pradhan, R Nayak, S Patra, PP Bhuyan… - Carbohydrate …, 2022 - Elsevier
As a significant public health hazard with several drug side effects during medical treatment,
searching for novel therapeutic natural medicines is promising. Sulfated polysaccharides …

Innate immune response to SARS-CoV-2 infection: From cells to soluble mediators

D Ricci, MP Etna, F Rizzo, S Sandini, M Severa… - International journal of …, 2021 - mdpi.com
The vulnerability of humankind to SARS-CoV-2 in the absence of a pre-existing immunity,
the unpredictability of the infection outcome, and the high transmissibility, broad tissue …

[HTML][HTML] COVID-19: An overview and a clinical update

A Krishnan, JP Hamilton, SA Alqahtani… - World journal of clinical …, 2021 - ncbi.nlm.nih.gov
The outbreak of coronavirus disease-2019 (COVID-19, previously known as 2019 nCoV)
caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in …

A novel hypothesis for COVID-19 pathogenesis: Retinol depletion and retinoid signaling disorder

AR Sarohan, M Kızıl, AÇ İnkaya, S Mahmud, M Akram… - Cellular signalling, 2021 - Elsevier
The SARS-CoV-2 virus has caused a worldwide COVID-19 pandemic. In less than a year
and a half, more than 200 million people have been infected and more than four million …

Cyanobacteria and algae-derived bioactive metabolites as antiviral agents: Evidence, mode of action, and scope for further expansion; a comprehensive review in …

B Pradhan, R Nayak, S Patra, PP Bhuyan, SR Dash… - Antioxidants, 2022 - mdpi.com
COVID-19—a severe acute respiratory syndrome disease caused by coronavirus 2 (SARS-
CoV-2)—has recently attracted global attention, due to its devastating impact, to the point of …

The rise of SARS-CoV-2 variants and the role of convalescent plasma therapy for management of infections

M Moubarak, KI Kasozi, HF Hetta, HM Shaheen, A Rauf… - Life, 2021 - mdpi.com
Novel therapies for the treatment of COVID-19 are continuing to emerge as the SARS-Cov-2
pandemic progresses. PCR remains the standard benchmark for initial diagnosis of COVID …

Pro-inflammatory CXCL-10, TNF-α, IL-1β, and IL-6: biomarkers of SARS-CoV-2 infection

AS Tripathy, S Vishwakarma, D Trimbake, YK Gurav… - Archives of …, 2021 - Springer
Currently, the world is witnessing the pandemic of COVID-19, a disease caused by the novel
coronavirus SARS-CoV-2. Reported differences in clinical manifestations and outcomes in …

A double edged-sword-the complement system during SARS-CoV-2 infection

LE Santiesteban-Lores, TA Amamura, TF da Silva… - Life sciences, 2021 - Elsevier
In the past 20 years, infections caused by coronaviruses SARS-CoV, MERS-CoV and SARS-
CoV-2 have posed a threat to public health since they may cause severe acute respiratory …

[HTML][HTML] The influence of the lectin pathway of complement activation on infections of the respiratory system

AS Świerzko, M Cedzyński - Frontiers in Immunology, 2020 - frontiersin.org
Lung diseases are among the leading causes of morbidity and mortality. Complement
activation may prevent a variety of respiratory infections, but on the other hand, could …